Pharmaceutical Technology6 天
Pimicotinib hydrochloride by Abbisko Therapeutics for Pancreatic Cancer: Likelihood of Approval
Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer.
What you should know about pancreatic cancer screening
Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...
Taiwan News4 天
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro ...
(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...
Pharmaceutical Technology6 天
AMT-676 by Multitude therapeutics for Pancreatic Ductal Carcinoma: Likelihood of Approval
AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.
来自MSN9 个月
Researchers determine oral bacteria accelerate pancreatic cancer development in mice
More information: Elias Saba et al, Oral bacteria accelerate pancreatic cancer development in mice, Gut (2024). DOI: 10.1136/gutjnl-2023-330941 Provided by Hebrew University of Jerusalem ...
GlobalData on MSN3 天
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
SciSparc says MitoCareX expands research to pancreatic cancer
SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into ...
Immuneering Gets Encouraging Data From Ongoing IMM-1-104 Trial For Pancreatic Cancer Treatment
(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...